Why is Strides Pharma Science Ltd ?
- Poor long term growth as Net Sales has grown by an annual rate of 9.32% and Operating profit at 15.52% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 6.58 times
- In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Strides Pharma for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at 5.44 times
Highest at 16.05%
Lowest at 0.67 times
Highest at Rs 235.95 cr.
Highest at Rs 141.92 cr.
Highest at Rs 204.91 cr.
Highest at 4.15 times
Highest at 19.75%
Highest at Rs 21.93
At Rs 446.82 cr has Grown at -22.46%
is 42.95 % of Profit Before Tax (PBT
Here's what is working for Strides Pharma
Operating Profit to Interest
PAT (Rs Cr)
Operating Profit (Rs Cr)
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
Debt-Equity Ratio
Operating Profit to Sales
PBT less Other Income (Rs Cr)
EPS (Rs)
Debtors Turnover Ratio
Here's what is not working for Strides Pharma
Non Operating Income to PBT
Non Operating Income






